Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MBOAT4 | Q96T53 | 18/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3871870 | 1.00 | GAA (0.42) | GAAHTTSMN1; SMN2MBOAT4ATM | |
| SCHEMBL3876315 | 1.00 | GAA (0.42) | GAAHTTSMN1; SMN2MBOAT4ATM | |
| SCHEMBL4921904 | 0.95 | GAA (0.45) | GAAHTTSMN1; SMN2MBOAT4ATM | |
| SCHEMBL3122488 | 0.95 | GAA (0.45) | GAAHTTSMN1; SMN2MBOAT4ATM | |
| SCHEMBL3133063 | 0.95 | GAA (0.45) | GAAHTTSMN1; SMN2MBOAT4ATM | |
| SCHEMBL3130141 | 0.95 | GAA (0.45) | GAAHTTSMN1; SMN2MBOAT4ATM | |
| SCHEMBL303749 | 0.95 | GAA (0.45) | GAAHTTSMN1; SMN2MBOAT4ATM | |
| SCHEMBL5402153 | 0.95 | GAA (0.45) | GAAHTTSMN1; SMN2MBOAT4ATM | |
| SCHEMBL3869997 | 0.92 | GAA (0.42) | GAAHTTSMN1; SMN2MBOAT4ATM | |
| SCHEMBL302684 | 0.92 | GAA (0.42) | GAAHTTSMN1; SMN2MBOAT4ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501383-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use for controlling harmful fungi | BASF AKTIENGESELLSCHAFT (DE) | 2009-03-10 | — | — | US | claimed |
| US-20070179061-A1 | Aminotriazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds | BASF AKTIENGESELLSCHAFT (DE) | 2007-08-02 | — | — | US | claimed |
| EP-1725559-A2 | 5,6-DIALKYL-7-AMINO-TRIAZOLOPYRIMIDINES, METHOD FOR THEIR PRODUCTION, THEIR USE FOR CONTROLLING PATHOGENIC FUNGI AND AGENTS CONTAINING SAID COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2006-11-29 | — | — | EP | claimed |
| WO-2005087771-A2 | 5,6-DIALKYL-7-AMINO-TRIAZOLOPYRIMIDINES, METHOD FOR THEIR PRODUCTION, THEIR USE FOR CONTROLLING PATHOGENIC FUNGI AND AGENTS CONTAINING SAID COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2005-09-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179061-A1 | Aminotriazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds | DPM1, ERG28, AGPS | GAA 1876/4885HTT 2705/4885SMN1; SMN2 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.